Bestewil Holding

Bestewil Holding is a private investment and holding company based in the Netherlands, primarily serving as the investment vehicle for Professor John Kastelein, a world-renowned expert in lipid metabolism. The company is a central figure in the Dutch biotechnology ecosystem, specializing in the formation and early-stage funding of life science companies focused on cardiovascular and metabolic diseases. Bestewil Holding has played a foundational role in several high-profile ventures, including Dezima Pharma, which was acquired by Amgen, and Staten Biotechnology, which entered into a strategic collaboration with Novo Nordisk. Through its portfolio companies, Bestewil supports the development of innovative therapies such as CETP inhibitors and monoclonal antibodies targeting ApoC-III. The firm acts as a bridge between academic research and commercial drug development, leveraging deep expertise in clinical trial design and lipidology. Currently, its most prominent interests include NewAmsterdam Pharma and NorthSea Therapeutics.